$0.29 4%
OGEN Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Oragenics

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.


Oragenics
Price $0.29
Target Price Sign up
Volume 198,240
Market Cap $3.7M
Year Range $0.27 - $3.07
Dividend Yield 0%
Analyst Rating 0% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2401.6M-1.6M-2.5M-2.4M0.000
Q2 '2401.4M-1.4M-2.3M-2.3M-0.509
Q1 '2401.8M-1.8M-2.5M-2.4M-0.701
Q4 '23-38,0001.8M-1.8M-13M-13M-4.138
Q3 '2316,0001.3M-1.3M-2M-2.1M-0.854

Insider Transactions View All

Telling Fred filed to sell 38,345 shares at $3.6.
December 1 '23
KOSKI ROBERT C filed to sell 1,102,295 shares at $0.1.
January 3 '23
KOSKI ROBERT C filed to sell 176,191 shares at $0.1.
January 3 '23
KOSKI ROBERT C filed to sell 1,144,652 shares at $0.2.
December 16 '22
KOSKI ROBERT C filed to sell 1,310,149 shares at $0.2.
December 15 '22

What is the Market Cap of Oragenics?

The Market Cap of Oragenics is $3.7M.

What is the current stock price of Oragenics?

Currently, the price of one share of Oragenics stock is $0.29.

How can I analyze the OGEN stock price chart for investment decisions?

The OGEN stock price chart above provides a comprehensive visual representation of Oragenics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Oragenics shares. Our platform offers an up-to-date OGEN stock price chart, along with technical data analysis and alternative data insights.

Does OGEN offer dividends to its shareholders?

As of our latest update, Oragenics (OGEN) does not offer dividends to its shareholders. Investors interested in Oragenics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Oragenics?

Some of the similar stocks of Oragenics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.